Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.77 USD | +5.51% | +26.60% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 454M | |
+18.31% | 125B | |
+13.92% | 108B | |
-6.69% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-15.15% | 16.34B | |
+0.22% | 13.56B | |
+25.09% | 11.59B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials